RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Medical Devices

Therapeutics

RVL Pharmaceuticals

Brian Markison

Nick Fee

Danielle Scandone

Jd Schaub

Tina Devries

Jarret Miller

James Schaub

Andrew Einhorn

The Sales and Business Development team at RVL Pharmaceuticals is dedicated to driving the commercialization of innovative products, such as UPNEEQ, by identifying market opportunities and building strong relationships with healthcare providers and key stakeholders in the ocular and medical aesthetics sectors. This team collaborates closely to execute strategic sales initiatives, enhance market penetration, and ultimately improve patient access to specialty treatments for underserved populations.

Sales and Business Development

Leadership Team

Finance and Accounting

Sales and Business Development

About

Team members

Other teams at RVL Pharmaceuticals

Leadership Team

Finance and Accounting